Pangea collaborates with Pharma/Biotech companies to develop the next generation of biomarker-guided precision oncology therapies

Pangea’s platform provides our collaborators a boost in the drug development process, both at the research and clinical levels.

We are currently focusing on the following areas:

Enhancing clinical programs through advanced biomarker-guided trials.

Expanding the indication range for existing therapies.

Identification of new molecular targets for targeted therapies.